National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Blinatumomab (Blincyto®) CD19+ BCP-ALL

Blinatumomab is indicated as  monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL)  in first or second complete remission with minimal residual disease greater than or equal to 0.1%.

NCPE Assessment Process Complete
Rapid review commissioned 19/08/2019
Rapid review completed 23/09/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price.*

 

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations February 2021.